2024-11-20 22:30:11
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
Corporate/ 2023-07-23
Harbour BioMed Announces Dosing of First...

CAMBRIDGE,Mass. and ROTTERDAM,Netherlands and SUZHOU,China,Jan. 4,2022-- Harbour BioMed ("HBM",HKEX: 02142) announced that,its nex...

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
Health/ 2023-07-22
Regor Therapeutics Announces U.S. FDA Au...

SHANGHAI,Dec. 28,2021-- On December 23,Regor Therapeutics,a clinical-stage biotech company,announced authorization from the US Food and Drug...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release